Glaukos CORP 8-K filings

Glaukos Corporation presented an investor presentation highlighting its innovative pipeline, strong financial health, and strategic focus on interventional glaucoma and keratoconus treatments.

Glaukos Corporation announced record second quarter 2026 financial results, with net sales soaring 50% year-over-year to $185.6 million, prompting an increase in full-year revenue guidance.

Glaukos Corporation's annual meeting saw stockholders vote on director elections, executive compensation, and auditor ratification, with all proposals passing.

Glaukos Corporation presented its latest investor materials in May 2026, detailing advancements in its interventional glaucoma and keratoconus therapies, alongside a robust product pipeline and positive financial outlook.

Glaukos Corporation presents its investor update, showcasing significant growth, a robust product pipeline, and strategic initiatives in interventional glaucoma and keratoconus.

Glaukos Corporation announced preliminary, unaudited net sales for Q4 and full year 2025, showing significant growth, and reaffirmed its 2026 revenue guidance.

Glaukos Corporation announced the FDA approval of Epioxa for keratoconus and detailed its robust pipeline and strategic growth initiatives in an investor presentation.

Glaukos Corporation announced record third quarter 2025 financial results, driven by strong sales growth and raised its full-year 2025 net sales guidance.

Glaukos Corporation highlights significant R&D investment, a deep pipeline of innovative eye care therapies, and strong financial performance in its latest investor presentation.

Glaukos Corporation announced record second quarter 2025 net sales of $124.1 million, a 30% year-over-year increase, and raised its full-year 2025 net sales guidance to $480 million to $486 million.

Glaukos Corporation announced the results of its May 29, 2025 annual meeting, where stockholders elected three Class I directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as its independent auditor.

Glaukos Corporation presents its May 2025 investor presentation, outlining its core growth strategy, pipeline advancements, and focus on dropless therapies for chronic eye diseases.

Glaukos Corporation announced record net sales of $106.7 million for Q1 2025, a 25% increase year-over-year, driven by strong performance in glaucoma and corneal health segments.

Glaukos Corporation presents its investor presentation, emphasizing innovation in chronic eye disease treatments and a core growth strategy focused on leading-edge innovation, dropless therapies, and commercial excellence.

Glaukos Corporation announces strong financial results for Q4 and full year 2024, driven by growth in glaucoma and corneal health franchises, and introduces 2025 net sales guidance of $475 million to $485 million.

Glaukos Corporation's investor presentation emphasizes its commitment to innovation and addressing unmet needs in chronic eye diseases through novel platforms and therapeutic areas.

Glaukos Corporation received approximately $53.2 million from financial institutions after unwinding a portion of capped call transactions related to its 2027 convertible notes.

Glaukos Corporation has entered into agreements to unwind a portion of its capped call transactions related to its 2027 convertible notes, receiving a cash settlement.

Glaukos Corporation details its commercial launch strategy for iDose TR, a groundbreaking glaucoma treatment, alongside updates on its robust pipeline and financial performance.

Glaukos Corporation announced record net sales for the third quarter of 2024, driven by strong growth in glaucoma and corneal health, and raised its full-year revenue guidance.

Glaukos Corporation has issued a notice to redeem all of its outstanding 2.75% Convertible Senior Notes due in 2027 for a total of $57.5 million.

Glaukos Corporation is set to launch its groundbreaking iDose TR glaucoma treatment, while also advancing its robust pipeline of ophthalmic innovations.

Glaukos Corporation has amended its initial Q2 earnings report to correct an accounting error related to convertible senior notes, which overstated interest expense and net loss.

Glaukos Corporation announced record second-quarter net sales of $95.7 million, a 19% increase year-over-year, and raised its full-year 2024 revenue guidance.

Glaukos Corporation finalized a debt-for-equity exchange, issuing 4,253,423 shares of common stock in exchange for $230 million of convertible notes.

Glaukos Corporation has announced agreements to exchange $230 million of its convertible senior notes due in 2027 for common stock and cash.

Glaukos Corporation's stockholders approved an amended incentive compensation plan and elected three directors at their annual meeting on May 30, 2024.

Glaukos Corporation is launching iDose TR, a groundbreaking long-duration glaucoma treatment, while also advancing a diverse pipeline of ophthalmic innovations.

Glaukos Corporation announced record net sales for the first quarter of 2024, driven by strong performance in both glaucoma and corneal health segments, and subsequently raised its full-year revenue guidance.

Glaukos Corporation details its commercial launch strategy for iDose TR, a groundbreaking glaucoma treatment, alongside updates on its extensive pipeline.